US still seeking clues to mystery illness afflicting diplomats and spies

Financial world news, market analysis, investment scam prevention tips and more ✔️ Learn all there is to know about the asset management industry. This magazine is crafted specifically for those who are interested in diving into the global asset management world. WASHINGTON (NYTIMES) - The US government has not determined what caused some US diplomats and intelligence officers to suffer from a mysterious, debilitating affliction while they were overseas, despite devoting vast resources over more than three years to investigating it, Secretary of State Mike Pompeo said Wednesday (Oct 21). Starting in late 2016, dozens of US officials and family members living in Cuba and China or travelling for work in other countries, including Russia, reported contracting an illness that has become known as Havana Syndrome, based on where it first publicly emerged. The symptoms included headaches, memory loss, vertigo, nausea, bloody noses and hearing strange sounds. Some US officials, including experienced CIA analysts, and scientists believe the victims were targeted by a foreign adversary wielding weaponised microwave radiation. Russia beamed microwaves at the US Embassy in Moscow in the 1970s and 1980s, and it has more recently harassed diplomats and fuelled violence against US soldiers. Other US officials and scientists say the injuries may be the product of a psychological illness, or even pesticides. Mr Pompeo, who was the CIA director before leading the State Department, said the government was still examining multiple theories in To keep reading about US still seeking clues to mystery illness afflicting diplomats and spies, Click on the link. Seoul, Korea
http://dlvr.it/Rk5B8T

Comments

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Coronavirus Hasn't Diminished Tech Stocks' Allure

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint